Whitehawk Therapeutics Inc (WHWK) 13F Filings: Institutional Buyers & Sellers (Q2 2026)

WHWK ranks #5126 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

WHWK is a top-conviction position for Yu Fan — at 20.6% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

WHWK is down 4.9% today, but institutions show net buying of $44.4M this quarter — a divergence between today's price move and the underlying institutional flow.

WHWK reported a net loss of $79.8M over the trailing twelve months.

• Not yet profitable — net loss of $79.8M over the trailing twelve months
• Revenue declined 100.0% year over year
• Net income declined year over year, from -$10.4M to -$79.8M
• Operating cash flow was negative, using $97.4M in cash
• Current ratio of 10.26x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.11x equity — within a conventional range